Beate Wieseler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4080772/publications.pdf

Version: 2024-02-01

20 papers	1,473 citations	623734 14 h-index	677142 22 g-index
22 all docs	22 docs citations	22 times ranked	1572 citing authors

#	Article	IF	Citations
1	Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ: British Medical Journal, 2010, 341, c4737-c4737.	2.3	456
2	Reporting bias in medical research - a narrative review. Trials, 2010, 11, 37.	1.6	361
3	Completeness of Reporting of Patient-Relevant Clinical Trial Outcomes: Comparison of Unpublished Clinical Study Reports with Publicly Available Data. PLoS Medicine, 2013, 10, e1001526.	8.4	111
4	Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ: British Medical Journal, 2012, 344, d8141-d8141.	2.3	88
5	Pathways to independence: towards producing and using trustworthy evidence. BMJ, The, 2019, 367, l6576.	6.0	79
6	New drugs: where did we go wrong and what can we do better?. BMJ: British Medical Journal, 2019, 366, l4340.	2.3	74
7	Generating comparative evidence on new drugs and devices before approval. Lancet, The, 2020, 395, 986-997.	13.7	59
8	Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. BMJ, The, 2020, 370, m2288.	6.0	39
9	Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports. BMJ, The, 2015, 350, h796-h796.	6.0	38
10	Finding studies on reboxetine: a tale of hide and seek. BMJ: British Medical Journal, 2010, 341, c4942-c4942.	2.3	28
11	Reporting a Systematic Review. Chest, 2010, 137, 1240-1246.	0.8	25
12	Early benefit assessment of new drugs in Germany â€“ Results from 2011 to 2012. Health Policy, 2014, 116, 147-153.	3.0	25
13	Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs. Biometrical Journal, 2016, 58, 43-58.	1.0	25
14	Access to regulatory data from the European Medicines Agency: the times they are a-changing. Systematic Reviews, 2012, 1, 50.	5.3	14
15	Impact of Inclusion of Industry Trial Results Registries as an Information Source for Systematic Reviews. PLoS ONE, 2014, 9, e92067.	2.5	14
16	ENDPOINTS FOR RELATIVE EFFECTIVENESS ASSESSMENT (REA) OF PHARMACEUTICALS. International Journal of Technology Assessment in Health Care, 2014, 30, 508-513.	0.5	11
17	Secrecy or transparency? The future of regulatory trial data. Cmaj, 2017, 189, E185-E186.	2.0	5
18	Beyond journal publications â€“ a new format for the publication of clinical trials. Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen, 2017, 120, 3-8.	0.9	3

#	Article	IF	Citations
19	From publication bias to lost in information: why we need a central public portal for clinical trial data. BMJ Evidence-Based Medicine, 2022, 27, 74-76.	3.5	3
20	Centralised Full Access to Clinical Study Data Can Support Unbiased Guideline Development, Continuing Medical Education, and Patient Information. Journal of European CME, 2021, 10, 1989172.	1.6	1